Clinical Trials
57 trialsNeoTENNIS
Fudan University
Evaluating Xihuang Pill to Improve the Efficacy of Neoadjuvant Chemotherapy for Breast Cancer
Zhejiang Provincial People's Hospital
A Phase II Study Evaluating the Efficacy and Safety of Pembrolizumab in Combination With Chemotherapy as Neoadjuvant Therapy for Triple-negative Breast Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
easy laugh
Shanghai Pudong Hospital
HIFU
The First Affiliated Hospital with Nanjing Medical University
A Study of Immunotherapy Combined With Neoadjuvant Therapy Versus Neoadjuvant Therapy for Breast Cancer
Shengjing Hospital
DDP
University of Bergen
Clinical Study of Chidamide Combined With Chemotherapy in Neoadjuvant Treatment of HR+/ HER2-BC
Shengjing Hospital
Chidamide Combined With Exemestane (+/- Goserelin) Versus Neoadjuvant Chemotherapy in Patients of Stage II-III HR-positive/HER2-negative Breast Cancer
Shengjing Hospital
Pyrotinib as Neoadjuvant Agent for Non-objective Response HER2-positive Early Breast Cancer
The First Affiliated Hospital with Nanjing Medical University
Neoadjuvant Study of Camrelizumab Plus Chemotherapy in Triple Negative Breast Cancer (TNBC)
Shandong Cancer Hospital and Institute
Study of Tislelizumab Plus Chemotherapy vs Chemotherapy as Perioperative Treatment in Participants With HER2 Negative Breast Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Trial of Adjuvant Chemotherapy in Breast Cancer Patients With Pathological Partial Response and Complete Response to Neoadjuvant Chemotherapy
RenJi Hospital
PRETTY
Sun Yat-sen University
SHR-1210 Combined With Albumin-bound Paclitaxel and Epirubicin Neoadjuvant for Triple Negative Breast Cancer
Henan Cancer Hospital
TENDENCY
Hebei Medical University Fourth Hospital
Breast Cancer Treatment Based on Organ-like Culture
Xijing Hospital
ESNDBCP
Zhejiang University
The Trial Comparing Dose-dense AC-T With TP as Adjuvant Therapy for TNBC With Homologous Recombination Repair Deficiency
ChineseAMS
The Efficacy and Safety of Abraxane Combined With Epirubicin as Neoadjuvant Chemotherapy in Breast Cancer
Zhejiang Cancer Hospital
PECP
Zhejiang Cancer Hospital
TACT2
Institute of Cancer Research, United Kingdom
Risk and Clinical Benefit of Chemotherapy and Intensive Endocrine Therapy for Luminal B1 Early-stage Breast Cancer
Shandong Cancer Hospital and Institute
Pathological Complete Response Rate in Locally Advanced Breast Cancer With FEC, EC-T, or TC as Neoadjuvant Chemotherapy
Shandong Cancer Hospital and Institute
SHH-CM
Clinica Universidad de Navarra, Universidad de Navarra
Lapatinib Plus Chemotherapy Versus Trastuzumab Plus Chemotherapy in HER2-positive Breast Cancer
Xijing Hospital
NNBC3-Europe
Martin-Luther-Universität Halle-Wittenberg
PERS
Sun Yat-sen University
Paclitaxel Followed by FEC Versus Paclitaxel and RAD001 Followed by FEC In Women With Breast Cancer
M.D. Anderson Cancer Center
PROMIX
Karolinska University Hospital
Neoadjuvant Chemotherapy for Operable Premenopausal Breast Cancer Patients
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Paclitaxel in Combination With Carboplatin Versus Paclitaxel Plus Epirubicin in Metastatic Breast Cancer
Tianjin Medical University Cancer Institute and Hospital
Neoadjuvant Chemotherapy With or Without Huaier Granule in Treating Women With Locally Advanced Breast Cancer That Can Be Removed By Surgery
Shandong University
A Study on Neoadjuvant Therapy for Her-2 Positive Breast Cancer and the Prognosis by Detecting CTCs
Hospital Affiliated to Military Medical Science, Beijing
Study of Optimizing Neoadjuvant Regimens in Subtypes of Breast Cancer
ChineseAMS
A Study of Genetic Based Chemotherapy Dosing for Breast Cancer Patients
AHS Cancer Control Alberta
Neoadjuvant Trial of Capecitabine for Axillary Lymph Node Positive Operable Breast Cancer
Guangxi Medical University
Combination Chemotherapy in Treating Women With Stage II or Stage III Breast Cancer
National Cancer Institute (NCI)
Epirubicin and Tamoxifen With or Without Docetaxel in Treating Postmenopausal Women With Breast Cancer
National Cancer Institute (NCI)
Combination Chemotherapy in Treating Women With Breast Cancer Who Have Undergone Surgery
National Cancer Institute (NCI)
Neoadjuvant Epirubicin, Cyclophosphamide, and Paclitaxel With or Without Gemcitabine in Treating Women Who Are Undergoing Surgery for Early Breast Cancer
National Cancer Institute (NCI)
Doxorubicin or Epirubicin and Cyclophosphamide in Treating Older Women With Invasive Breast Cancer
National Cancer Institute (NCI)
Combination Chemotherapy and Trastuzumab in Treating Women With Stage I, Stage II, or Stage III HER2-Positive Breast Cancer
National Cancer Institute (NCI)
Cyclophosphamide, Methotrexate, and Fluorouracil, With or Without Epirubicin Hydrochloride, in Treating Women Who Have Undergone Surgery for Breast Cancer (Group III Closed to New Patients as of 12/7/2009)
National Cancer Institute (NCI)
Beva
Association Tunisienne de lutte Contre le Cancer
Regimens Comparison for Breast Cancers of Positive Lymph Nodes
ChineseAMS
Efficacy and Safety Study of Trastuzumab and Paclitaxel Based Regimens to Treat HER2-positive Breast Cancer
Fudan University
NACprotocol
Auxilio Mutuo Cancer Center
The Trial Comparing Dose-dense AC-T With PC as Adjuvant Therapy for TNBC
ChineseAMS
CBCRT01
Xijing Hospital